Pelthos Posts $2.04 GAAP Loss Per Share as Zelsuvmi Revenue Rises 114%

Pelthos Therapeutics Inc. posted a $2.04 GAAP loss per share in the third quarter of 2026, while net product revenue from its lead product, Zelsuvmi, rose 114% from a year earlier.

Zelsuvmi generated $15.2 million in net product revenue, compared with $7.1 million in the third quarter of 2025. Net product revenue declined 1% from the second quarter of 2026.

Pelthos recorded total revenue of $15.4 million for the quarter. Its net loss narrowed to $7.9 million from $16.2 million a year earlier.

The results follow Pelthos’ October merger agreement with Castle Creek Biosciences. Pelthos expects the merger to close by the end of March 2027, pending approval from Castle Creek stockholders and satisfaction of other customary conditions.